It should be noted that AMPK activators, such as A-769662, PF-739, or metformin, have been shown to ameliorate the symptoms of MAFLD-hepatic steatosis, inflammation, liver injury, and fibrosis via different mechanisms [44]; however, global activation of AMPK by MK-8722 has been observed to result in cardiomyocyte hypertrophy, possibly due to the induction of cardiac glycogen synthesis [45]. Here, PRKAA1 is linked to fatty liver disease.